Zura Bio (ZURA) CEO receives 2.93M stock options with 2036 expiry

Rhea-AI Filing Summary

Zura Bio Ltd reported that Chief Executive Officer and director Sandeep Chidambar Kulkarni received an employee stock option grant on January 21, 2026. The option covers 2,934,107 Class A Ordinary Shares at an exercise price of $6.32 per share and expires on January 21, 2036.

According to the vesting terms, one fourth of the options will vest on January 21, 2027, and the remaining options will vest in equal quarterly installments, with one twelfth of the remaining shares vesting each quarter. Vesting is conditioned on the CEO’s continuous service with the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Sandeep Chidambar

(Last) (First) (Middle)

C/O ZURA BIO LIMITED

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON NV 89014

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Share Option (Right to Buy)	$6.32	01/21/2026		A		2,934,107		(1)	01/21/2036	Class A Ordinary Shares	2,934,107	$0	2,934,107	D

Explanation of Responses:

1. One fourth (1/4th) of the shares subject to the option award shall vest on January 21, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zura Bio (ZURA) disclose?

Zura Bio disclosed that Chief Executive Officer and director Sandeep Chidambar Kulkarni received an employee stock option grant covering 2,934,107 Class A Ordinary Shares on January 21, 2026.

What is the exercise price of the new options granted to Zura Bios CEO?

The employee share options granted to the CEO have an exercise price of $6.32 per underlying Class A Ordinary Share.

How many shares are covered by the Zura Bio CEOs option grant and how many are held after the transaction?

The option grant covers 2,934,107 shares, and the number of derivative securities beneficially owned following the transaction is also 2,934,107 options.

What is the vesting schedule for the Zura Bio (ZURA) CEO stock options?

One fourth of the options vest on January 21, 2027. The remaining options vest in equal quarterly installments, with one twelfth of the remaining shares vesting each quarter, subject to continuous service.

When do the newly granted Zura Bio CEO options expire?

The employee share options granted to the CEO are scheduled to expire on January 21, 2036, if not exercised or forfeited earlier under their terms.

Is the Zura Bio CEOs option grant held directly or indirectly?

The Form 4 indicates that 2,934,107 derivative securities from this award are held with direct (D) ownership.